TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Notes to Consolidated Financial Statements (Continued)
de minimis amount to well over $100 million. Teva denies any liability and has filed a motion for reconsideration of the courts June 28, 2017 order. Teva will continue to
argue that any damages and penalties should be significantly less than the amount sought by the state. In August 2013, in the Mississippi case against Watson, the court ruled in favor of the state, awarding $12.4 million in compensatory damages
and civil penalties. In March 2014, the court awarded the state an additional $17.9 million in punitive damages. A provision for these amounts has been included in the financial statements. Watson is appealing both the original and the punitive
Several qui tam complaints have been unsealed in recent years as a result of government decisions not to
participate in the cases. The following is a summary of certain government investigations, qui tam actions and related matters.
December 2009, the U.S. District Court for the District of Massachusetts unsealed a complaint alleging that numerous drug manufacturers, including certain Teva subsidiaries (including Actavis), violated the federal False Claims Act in connection
with Medicaid reimbursement for certain vitamins, dietary supplements and DESI (Drug Efficacy Study Implementation) products that were allegedly ineligible for reimbursement. The U.S. Department of Justice (DOJ) declined to join in the
matter. The defendants, including Teva, filed a motion to dismiss, which was granted in February 2013. The plaintiffs deadline to appeal the dismissal has not yet expired.
In March 2013, a federal False Claims Act complaint filed against Cephalon in the U.S. District Court for the Southern District of New York
was unsealed. The case was transferred to the Eastern District of Pennsylvania. The complaint alleges off-label promotion of Treanda® and
Fentora®. The court granted Cephalons motion to dismiss the Fentora® claims and denied Cephalons motion to dismiss the
Treanda® claims. In January 2014, a separate federal False Claims Act complaint that had been filed in the U.S. District Court for the Eastern District of Pennsylvania was served on Cephalon.
The complaint alleges off-label promotion of Fentora®, Nuvigil® and Provigil®.
The court dismissed the Fentora® claims and denied Cephalons motion to dismiss the Provigil® and Nuvigil® claims. In August 2015, Cephalon submitted a motion to modify the courts order denying its motion to dismiss the relators
Provigil® claims. In February 2016, the court granted Cephalons motion for judgment on the pleadings as to Provigil® claims that
allegedly occurred prior to February 28, 2008. The relators motion for reconsideration was denied without prejudice. The Company has reached an agreement in principle to settle both of these matters and a provision has been included in
the financial statements in 2017.
In September 2013, the State of Louisiana filed a petition seeking penalties and unspecified damages
against 54 pharmaceutical companies, including Teva and Actavis. The complaint alleges that the defendants defrauded the state by falsely representing that its products were FDA-approved drugs, which allegedly caused the state Medicaid program to
pay millions of dollars in reimbursement claims for products that it would not otherwise have covered. The case was dismissed without prejudice in September 2015, with the court finding that the state was not a proper plaintiff. The state appealed,
and on October 21, 2016 the state court of appeals affirmed the trial courts ruling in part and reversed in part. The state and the defendants appealed to the Louisiana Supreme Court, which denied all parties appeals on
March 13, 2017, and remanded the case to the trial court. On March 31, 2017 the trial court ordered all defendants to respond to the first amended petition on or before May 11, 2017.
In January 2014, Teva received a civil investigative demand from the U.S. Attorney for the Southern District of New York seeking documents and
information from January 1, 2006 related to sales, marketing and promotion of Copaxone® and Azilect®. The demand states that the
government is investigating possible civil violations of the federal False Claims Act. In March 2015, the docket in this matter and a False Claims Act civil qui tam complaint concerning this matter were unsealed by the court, which revealed
that the U.S. Attorney had notified the court in November 2014 that it had declined to intervene in and proceed with the lawsuit. The qui tam relators, however, are moving forward with the lawsuit. In June 2015, Teva filed motions to dismiss
the complaint. In February 2016, the court stayed its decision on the relators claims based on state and local laws, denied Tevas motions to dismiss the False Claims Act claims, and instructed the relators to amend their complaint with
additional information. In March 2016, the relators filed an amended complaint, which Teva answered in April 2016. The parties are currently engaged in discovery.
Beginning in May 2014 various complaints have been filed against Teva and Cephalon, along with several other pharmaceutical companies, by a
number of cities, counties and states across the country. Actions currently pending against Teva and Cephalon have been brought by Ohio, Mississippi, and Oklahoma, the Cities of Dayton and Lorain, Ohio, the City of Chicago, Union County and Jersey
County, Illinois, Santa Clara, Orange and San Joaquin counties in